These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34729147)

  • 1. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.
    Hung YT; Lin YJ; Chiu HY; Huang YH
    Ther Adv Chronic Dis; 2021; 12():20406223211046685. PubMed ID: 34729147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab.
    Chiang CY; Tsai TF
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):301-306. PubMed ID: 33400156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
    Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period.
    Chan Y; Tong BSB; Ngan PY; Au CS
    Psoriasis (Auckl); 2021; 11():53-58. PubMed ID: 34104632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study.
    Galluzzo M; Tofani L; Lombardo P; Petruzzellis A; Silvaggio D; Egan CG; Bianchi L; Talamonti M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32659978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
    Puig L; Daudén E; Cuervas-Mons M; Novella C; Guisado C
    J Eur Acad Dermatol Venereol; 2023 Aug; ():. PubMed ID: 37567861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
    Bardazzi F; Viviani F; Merli Y; Di Lernia V; Peccerillo F; Conti A; Lasagni C; Tabanelli M; D'Adamio S; Di Nuzzo S; Cortellazzi C; Filippi F
    Expert Opin Biol Ther; 2022 Dec; 22(12):1561-1566. PubMed ID: 35388713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
    Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
    Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China.
    Yang J; Hu K; Li X; Hu J; Tan M; Zhang M; Kuang Y; Lv C; Chen J
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):477-485. PubMed ID: 36481840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
    Gooderham M; Vender R; Crowley J; Hong HC; Feely M; Garrelts A; See K; Konicek B; Green L
    Dermatol Ther (Heidelb); 2024 Feb; 14(2):441-451. PubMed ID: 38332436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
    Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
    Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):629-640. PubMed ID: 36585606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.